An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in Schizophrenia
Completed · Not applicable
Conditions studied: Obesity, Weight Loss, Schizophrenia
In brief
The aim of this study is to collect pilot data to compare the effectiveness of treatment with Alpha Lipoic Acid (ALA) for reduction in body weight in 40 obese outpatients with schizophrenia or schizoaffective disorder in an open-label pilot trial. The investigators also plan to test the feasibility of utilizing ALA as a weight loss agent for obese outpatients with schizophrenia or schizoaffective disorder in terms of tolerability, schizophrenia symptoms, cognition and side effects. We have run a total of 12 non-diabetic participants and are now recruiting diabetic patients in hopes of comparing the two groups.
Key facts
- Study ID
- NCT01355952
- Run by
- Yale University
- People needed
- 17
- Starts
- 2011-05-01
- Expected to finish
- 2012-12-01
- Last updated by the study team
- 2015-11-05
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 18 to 70 years;
- Meet DSM-IV criteria for schizophrenia or schizoaffective disorder (confirmed from clinical chart)
- Overweight, as defined with a BMI of equal to or greater than 27 kg/m²;
- Be on a stable dose of antipsychotic medication; i.e. at least one month with no dosage change, and two months from an antipsychotic switch;
- Deemed to be symptomatically stable by the clinical staff in the last two months;
- English speaking
You may not qualify if…
- A history of dementia, mental retardation or other neurological disorder that may interfere with study ratings;
- Not capable of giving informed consent for participation in this study;
- Ongoing pregnancy;
- A medical disorder that is known to cause obesity
Where it is running
- Connecticut Mental Health Center — New Haven, Connecticut, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.